Buy or not to buy Curevec shares? Our future forecast 2022!

throttll
October 9, 2021
We cover the basic data on the Curevac share: price, reviews, prospects, analysis, forecasts, recommendations, history and tips on how and where to buy Curevec shares online easily.
Buy or not to buy Curevec shares Our future forecast 2021!

Investors in BioNTech or Pfizer have invested and recently suffered a damper. On November 9, 2020, the companies announced that their corona vaccine was ready and was only waiting for an examination by the FDA ( Food and Drug Administration ). However, there is another candidate in the race for the best and most effective vaccine: Curevac.

The biopharmaceutical company from Tübingen enters the race with a big plus. On November 12 November 2020, the company announced that their vaccine was not only successful but could also be kept in the refrigerator for up to 3 months. The cooling requirements are, therefore, a great advantage over the competitors.

Accordingly, there is a great question among investors as to whether it is worth investing in shares of Curevac. Is now the right time to start? How will Curevac develop? We cover the basic data on the Curevac share: price, reviews, prospects, analysis, forecasts, recommendations, history and tips on how and where to buy Curevec shares online easily.

 

Table of Contents

Buying Curevac shares – what should you watch out for?

You should pay attention to the following points when buying Curevac shares:

  • Why should you invest in Curevac stocks? Based in Tübingen, Germany, the company specialises in the research and development of drugs based on the messenger molecule mRNA. In addition to developing specialised a corona vaccine, the biopharmaceutical company is also concerned with vaccines against Lassa fever, yellow fever and rabies.
  • Where can I buy Curevac shares? Curevac can be bought from any online broker. However, we recommend our test winner Capixal. In our opinion, the provider is the absolute best stock broker currently on the market. On Capixal, you can buy stocks and ETFs completely free of charge.
  • What can the future of the Curevac share look like? Depending on the success of the corona vaccine, the future looks very promising for stocks. If the manufacturer keeps what he promises, high returns can be possible.

The best brokers for buying Curevac stocks

Rating

Min. Deposit

Min. Spread

Assets

Views

Positive Reviews

Negative Reviews

Likes

4.9/5
250
0.07
  • Commodities
  • Forex 40 +
  • Metals
  • Stocks
  • Indices
  • Cryptocurrencies
85
2
4.5/5
250
0.07
  • Metals
  • Forex
  • Indices
  • Cryptocurrencies
  • Commodities
  • Stocks

 

254
82
3
58
4.9/5
250
0.07
  • Forex 40+
  • Metals
  • Commodities
  • Stocks
  • Indices
  • Cryptocurrencies

 

480
80
3
50
Buying Curevac shares in 3 steps: Our guide

1. Registration with a broker

In order to be able to buy the Curevac share, you first have to register and log in with a broker of your choice. In order to be able to buy a share, you always need a broker who buys the share on the market and then holds it in custody. It is advisable to pay particular attention to deposit protection. Should the broker file for bankruptcy, the shares still belong to you. Anyone who waives this deposit protection will be left without shares in the event of the broker’s bankruptcy.

If stock selection and evaluation are too complicated, a social trading platform can also be a good solution. Here you simply follow an experienced trader and automatically copy the trader’s trading decisions.

Our broker recommendation at this point is Capixal – with state-guaranteed deposit protection of up to 20,000 euros and 0% commission when buying shares, Capixal is our test winner broker. To register with Capixal, click here.

If you have decided on a broker, you log in with your data and verify your email address and other data.

Capixal

2. First deposit

After registering, you need to decide how much to invest in stocks. We generally recommend that you never invest more than 5% of your capital in a single share. 

Once you have decided on the amount you want to invest, click the ” Add Money ” button.

You can now choose from various deposit methods, including PayPal, credit card or bank transfer. It should be noted that a bank transfer usually takes 2-3 working days for the credit to arrive on the customer account. However, if you want to have your money in your account faster, other payment methods are available.

Below is an overview of all the payment methods available at Capixal:

Payment optionPossible?
Buy Curevac shares with a credit card✔️
Buy Curevac shares with PayPal✔️
Buy Curevac shares with Skrill✔️
Buy Curevac shares by bank transfer✔️
Buy Curevac shares with Neteller✔️
Buy Curevac shares with UnionPay✔️

3. Buy Curevac shares

After the deposit, the money appears in your account under the menu item “Account”. First, find the Curevac share using the search bar above and select it. Then click on the “Trade” button.

A small window will open where you can set the price and the number of shares you want to buy. You can also set stop-loss and take-profit, i.e. at which price the share should be sold again in the event of a profit or loss. The two fields are optional.

With the field Leverage, you can buy a “real share” with single leverage or a CFD (with double or multiple leverages).

The purchase is completed with a click on “Place order,” and the share appears in your portfolio.

What is Curevac?

Curevac NV is a biopharmaceutical company with legal headquarters in the Netherlands. The headquarters of the company is located in Tuebingen. The company was founded in 2000 and currently employs 500 people. The annual turnover in 2019 was EUR 17.4 million.

The company specializes in the research and development of drugs based on the messenger molecule mRNA. Thus, Curevac is mainly dedicated to cancer patients. In 2019, it was announced that the vaccine alliance CEPI and Curevac had reached an agreement worth US $ 34 million. This should enable a quick supply of RNA vaccines against already known diseases such as Lassa fever, yellow fever and rabies.

At the end of January 2020, Curevac received another grant from CEPI in the amount of EUR 8.3 million for the development of a vaccine against COVID-19.

Buy or not to buy Curevec shares Our future forecast 2021!

Curevac share price, price and key figures

With its IPO on the US technology exchange Nasdaq, Curevac raised fresh money for the development of a corona vaccine. Initially, 13.33 million shares were issued at $ 16 each, adding $ 213 million to the company.

Like many young biotech companies, the Tübingen-based company needs money because development devours a lot of money and, without a market-ready product, income will only flow sparingly. For 2019, CureVac posted sales of 17.4 million euros and a loss of 99.9 million euros.

On Thursday, the Curevac climbed share on the NASDAQ by 12.51 per cent to 69.69 USD. The current price of the stock is US $ 74.64 (NASDAQ). The price is currently trading at EUR 63.50 on the Frankfurt Stock Exchange (5CV) (as of November 19, 2020). When it went public, the price was EUR 62.90. The previous low was EUR 62.35, while the high was EUR 63.80.

Curevac share price current (price)

The current price (as of March 16, 2021) for the Curevac share is € 78.00 on the Frankfurt trading venue and $ 92.85 on the NASDAQ in New York.

Since it was listed on the stock exchanges, the Curevac share has been able to generate huge profits for investors. At the Frankfurt Stock Exchange, the issue price in June 2020 was € 40.58 per share. To date, the share on the Frankfurt Stock Exchange has grown by 92%.

The stock first traded on NASDAQ in New York in August 2020 at a price of $ 55.90. With a current price of $ 92.85, the stock was able to achieve a growth of 66%. Therefore, investing in Curevac would have been an excellent investment.

Curevac Stock Exchanges: New York or Frankfurt?

The Curevac share is traded on both the NASDAQ in New York and the Frankfurt Stock Exchange. However, the two trading venues charge high fees for you as an investor for trading in Curevac shares.

We, therefore, recommend trading Curevac shares via Capixal due to the lower fees. Thanks to the lower trading fees and many years of experience in the market, Capixal is the right broker for you if you want to trade Curevac shares.

Curevac stock metrics

Curevac share analysis – What is the current position of the Curevac share

The share is currently at a price of € 78.00 (as of March 16, 2021) on the Frankfurt Stock Exchange and holds a lot of upside potential for you investors.

In June 2021, the approval of the vaccine against Covid-19 from Curevac is expected at the latest. It is precise because of this positive news that the share price of the Tübingen-based company could move upwards.

Not only with regard to vaccinations against COVID-19, but this approval would also mean significant progress. The approval would ultimately also confirm that the company can use mRNA technology to develop treatment methods against other diseases successfully. The potential in this area is almost limitless, and the technology is expected to be useful in the treatment of various cancers and rare diseases.

Therefore there is a lot of potential in the share, and in the current phase, the Curevac share could represent a good investment.

News and history of the Curevac share

The IPO of Curevac took place on August 14, 2020, at the American technology exchange Nasdaq. With an issue price of $ 16 and proceeds of $ 245 million, the company was valued at approximately $ 2.3 billion.

As part of the IPO, the former Curevac Aktiengesellschaft (AG) was converted into a Dutch public limited company, Curevac NV. At the same time, there was a capital increase of EUR 100 million.

After the IPO and additional financing by Dietmar Hopp (German entrepreneur and co-founder of the SAP company), the following shareholders held over 5%: Dievini Hopp BioTech Holding (49.5%), Kreditanstalt für Wiederaufbau (17.0%) and Glaxo (8.5%). Management boards and supervisory boards jointly hold 1.1%.

At the beginning of September, it was announced that Curevac would receive a grant of EUR 252 million from the federal government to accelerate the development of the corona vaccine.

Buy or not to buy Curevec shares Our future forecast 2021!

What are the advantages of buying?

The private bank Berenberg has left the rating for Curevac after a conference with the CEOs of BioNTech and Curevac at “Buy” with a target price of 72 euros. So things are looking perfect for the stock right now.

Should Curevac keep its promises, expectations would also be fulfilled. Curevac itself states that its active ingredient can be kept in the refrigerator for up to 3 months. Compared to Pfizer and BioNTech, this would be a huge advantage. Their vaccine must be stored and transported at -70 degrees Celsius. This would be a logistical nightmare. Should Curevac actually advance its vaccine, it would ensure the company an all-time high in 2021.

Most recently, the Curevac share started trading in Frankfurt and rose by 1.7 per cent to EUR 63.55. In the short term, the CureVac share reached its current high for the day at EUR 63.55. The share opened the trading session at EUR 62.90. Most recently, 3,264 CureVac shares changed hands.

With an average price target, the analysts’ forecasts for the CureVac share are EUR 72.00.

 

What are the advantages of selling?

The competition never sleeps. Especially in times of the corona pandemic, more and more pharmaceutical companies are working on the development of a vaccine. Even if BioNTech and Pfizer have already applied to the FDA for approval, that doesn’t mean the vaccine will be a success. Another candidate for the vaccine is Moderna. 

BioNTech, Pfizer and Moderna currently report 95% effectiveness. However, the cooling of the vaccines will play a big role. And here, Curevac is clearly ahead. This should be a disappointment if contrary to all expectations; the share may suffer a significant loss in value.

However, analysts and experts are currently recommending a clear buy of the share.

Should you invest in Curavec shares? Is it still worth it?

  • A strong upward trend in the share since the IPO
  • COVID-19 vaccine could be the breakthrough for Curevac
  • Analysts predict high price targets
  • Current clear buy recommendation for the share
  • The IPO took place in August 2020 – comparative values ​​and share price developments can hardly be assessed.
  • Big competition in the pharmaceutical industry

Curevac share forecast, dividend and price target 2021

Curavec share price target:

After the latest price gains, Curevac received a clear buy recommendation from Berenberg. The current target price is USD 72. Based on the current price level, this corresponds to around 20 per cent upside potential.

Curavec share forecast:

The forecasts point to a clear upward trend. However, even if BioNTech, Pfizer, or Moderna put their vaccine on the market first, that doesn’t mean Curevac will stop its study. Due to the current situation, there is an urgent need for further vaccines on the market. Because while pharmaceutical companies are constantly producing new reports of success in the search for a vaccine against Covid-19, politicians are trying to secure as much of the drugs as possible in advance.

Precisely because of this, Curevac received EU funding for the further development of its vaccine.

Curavec share dividend:

Since the IPO did not occur until August 2020, there is no data on the last or announced dividend.

Curevac shares in comparison

The race for the corona vaccine is in full swing. Several pharmaceutical companies are currently working on a vaccine. Pfizer recently announced that it is already in the 3rd phase. The expectations are correspondingly high. So how does the Curevac share compare to the other pharmaceutical companies? Here is a brief overview:

Pfizer share

  • Second largest pharmaceutical giant in the world
  • Specialized in mRNA technology
  • Cooperation with BioNTech
  • Study shows a 95% effect of the corona vaccine
  • Pfizer has already had severe slumps in the past
  • Corona vaccine is still awaiting FDA approval
  • Cooling the vaccine at -70 degrees Celsius makes distribution and storage more difficult

Moderna share

  • US biotech company will present its study with 30,000 subjects in November
  • Corona vaccination efficiency is 95%
  • With a little luck, the vaccine will be granted US emergency approval
  • High losses are accepted
  • In the third quarter, the net loss doubled to $ 234 million
  • High speculation – it all depends on the potential of the technology platform.

Astra-Zeneca share

  • British company whose project for a vaccine is furthest advanced
  • Revenue of over $ 24 billion in 2019
  • Meanwhile belongs to one of the stock exchange favourites in the pharmaceutical sector
  • Share price plummeted after BioNTech announced
  • Share price fluctuations very strongly
  • Big problems during the study: several sick people and one dead
  • Study continues despite the illness of test subjects

Fees when buying Curevac shares

We compare the fees of the largest brokers with the following example:

  • Purchase of Curevac shares worth € 1,000
  • Hold the Curevac share for one month and then sell
  • No course changes in the 30 days

With these assumptions, we now compare the fees of Libertex, Capixal & Plus500 :

ProvidersLibertexCapixalPlus500
Depositfor freefreefor free
Purchase fees€ 2.20free3.08%
Holding feesfor freefree0.05%
Sales charges€ 2.20Spreads3.08%
Total fees€ 4.40Reasonable€ 92.32

Buy or not to buy Curevec shares Our future forecast 2021!

Conclusion: Is Curevac stock a good investment?

One thing is clear: we need a corona vaccine. One company alone will not be enough here. Curevac is a relatively new pharmaceutical company that went public in August 2020, but the company is already expecting a lot.

The company announced that it is expanding its production of a vaccine. A European network is expected to produce up to 300 million doses in the coming year. Accordingly, Curevac works with several experienced partners in Europe.

Curevac also has a significant advantage over its competition. The vaccine should be able to be stored at only -5 degrees Celsius. This would make distribution and storage much easier.

Given the promising expectations, now is the right time to invest in the stock. Should Curevac keep its promises, shares could skyrocket in 2021. Investors, as well as analysts, are currently very optimistic.

 

4.9
4.9/5

Our recommendation: Trading at Investby

Our recommendation: Trading at Investby

  • The broker provides an Islamic Account
  • It provides a dedicated account manager
  • Receive customised investment news
  • Trade with a variety of assets
  • There’s no deposit limit
ABinvesting Review
4.5
4.5/5

Our recommendation: Trading at ABInvesting

  • Acknowledge the financial markets through education material 
  • Free VPS is available 
  • Get a swap discount of 50 per cent 
  • Islamic Account is available to traders 
  • Select account types of your interest
4.9
4.9/5

Our recommendation: Trading at PrimeFin

  • Fifth decimal available 
  • Spreads begin from 0.03 pips
  • Commission is zero  
  • Full 10-hour support  
  • News alerts and VPS for traders

FAQs

With the encouraging data, the Curevac share has also jumped significantly ahead of the IPO. According to analyzes, all signs are currently pointing to BUY. Curevac only went public in August 2020, but the share has continued to gain since then. An investment could be worthwhile here.

Curevac has been listed on the largest electronic exchange, the American Nasdaq, since it went public. It is also listed on the Frankfurt Stock Exchange (5CV) and can be traded there.

The article introduces some ways in which you can quickly get hold of your own Curevac share. If you do not want to purchase the share directly, you also have the option of using CFDs to bet on rising or falling prices.

you can buy CureVac N.V. stock in any dollar amount, or any other fund or stock you know on Capixal

Get a Callback

A trusted broker will contact you today.

Name(Required)